Milea Timbergen

46 References 1. Fletcher CDM, Bridge JA, PCWH, F M. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. Press: Lyon: IARC; 2013 2. Wu C, Nik-Amini S, Nadesan P, Stanford WL, Alman BA. Aggressive Fibromatosis (Desmoid Tumor) Is Derived from Mesenchymal Progenitor Cells. Cancer Res. 2010;70(19):7690-7698. 3. van Broekhoven DL, Grunhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. 4. Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131. 5. Reitamo JJ, Hayry P, Nykyri E, Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665-673. 6. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. DIAGN MOL PATHOL. 1997;6(2):98-101. 7. Lopez R, Kemalyan N, Moseley HS, Dennis D, Vetto RM. Problems in diagnosis and management of desmoid tumors. Am J Surg. 1990;159(5):450-453. 8. Hunt RT, Morgan HC, Ackerman LV. Principles in the management of extra-abdominal desmoids. Cancer. 1960;13:825-836. 9. Urist MR. Trauma and neoplasm; report of a case of desmoid tumor following simple fracture of the radius and ulna. Am J Surg. 1957;93(4):682-688. 10 . Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. AM J SURG. 1986;151(2):230-237. 11 . De Marchis ML, Palmirotta R, Picariello L, Della-Morte D, Ferroni P, Roselli M, et al. Mutational analysis of the APC gene in FAP-associated desmoid tumors. Anticancer Res. 2014;34(10):5882-5883. 12 . Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). European Journal of Surgical Oncology. 2009;35(1):3-10. 13 . Bertario L, Russo A, Sala P, Eboli M, Giarola M, D’Amico F, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95(2):102-107. 14 . Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462-468. 15 . Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587-2593. 16 . Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096-4102. 17 . Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. European Journal of Cancer. 2015:186-192. 18 . Gronchi A. NCT02547831 -Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/ NCT02547831; 19 . Bonvalot S. NCT01801176 - Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01801176?cond=NCT01801176&rank=1 2